Management of immunotherapy colitis: Special considerations in the COVID-19 era.

Grover, Shilpa; Bond, Sheila A; Mansour, Michael K; Friedman, Sonia

Grover, Shilpa; Bond, Sheila A; Mansour, Michael K; Friedman, Sonia.

Grover S; Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Bond SA; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Mansour MK; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Friedman S; Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Cancer ; 126(21): 4630-4633, 2020 11 01.

Article in English | MEDLINE | ID: covidwho-713429

Subject(s)

COVID-19 Drug Treatment; COVID-19/etiology; Colitis/chemically induced; Immunotherapy/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents, Immunological/adverse effects; Antiviral Agents/therapeutic use; COVID-19/diagnosis; Carcinoma, Non-Small-Cell Lung/therapy; Colitis/diagnostic imaging; Colitis/drug therapy; Diarrhea/chemically induced; Diarrhea/virology; Feces/chemistry; Female; Glucocorticoids/therapeutic use; Humans; Leukocyte L1 Antigen Complex/analysis; Lung Neoplasms/therapy; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colitis / COVID-19 / COVID-19 Drug Treatment / Immunotherapy Type of study: Case report / Diagnostic study Limits: Female / Humans / Middle aged Language: English Journal: Cancer Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google